Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rentokil to sell France Workwear for €410m

(Sharecast News) - Rentokil Initial said on Wednesday that it has agreed to sell its Workwear business in France to H. I. G Capital for around €410m (£344m). France Workwear comprises Rentokil Initial's workwear, flat linen and clean room business in France.

Net cash proceeds are expected to be about €370m and the deal is expected to complete in the fourth quarter of this year.

The company said the sale positions it "more clearly as a streamlined Pest and Hygiene & Wellbeing business, enabling the group to effectively concentrate resources to better capitalise on the large, attractive long-term growth markets within these core areas".

Once the France Workwear business is sold, Rentokil will be a business with revenue comprising around 80% Pest and 20% Hygiene & Wellbeing.

Rentokil also said the deal should enhance its capital efficiency through a meaningful reduction in capital expenditure requirements and improved cash flow, with a benefit to the free cash conversion percentage of approximately 100 basis points.

Net proceeds will be used for general corporate purposes including deleveraging the balance sheet while continuing to invest in the core business organically, as well as investing for growth through bolt-on M&A.

Chief executive Andy Ransom said: "This transaction is a further important step in the execution of our strategy to focus the company on Pest Control and Hygiene & Wellbeing, where we are a market leader.

"Over recent years we have been reshaping our portfolio towards higher growth markets and lower capital expenditure operations. In 2015, Pest Control accounted for just 44% of group revenue, today it's above 80%. This simplifies our business, strengthens our balance sheet, and enhances cash generation."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.